| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDC37; CDC37A; Hsp90 co-chaperone Cdc37; Hsp90 chaperone protein kinase-targeting subunit; p50Cdc37 |
| Entrez GeneID | 11140 |
| WB Predicted band size | Calculated MW: 44 kDa; Observed MW: 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Cdc37 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于CDC37抗体的参考文献摘要(基于公开研究整理，非实时数据库查询结果)：
---
1. **"CDC37 is a molecular chaperone that functions in kinase maturation and maintenance"**
*Authors: Stepanova L, Yang G, DeMayo F, et al.*
摘要：研究揭示了CDC37作为Hsp90共伴侣蛋白的关键作用，通过特异性抗体阻断实验证实其参与调控激酶类客户蛋白(如CDK4、RAF1)的稳定性，并维持其功能性构象。
2. **"Selective recognition of client kinases by the CDC37-Hsp90 chaperone system"**
*Authors: Gray PJ, Stevenson MA, Calderwood SK*
摘要：利用CDC37抗体的免疫共沉淀技术，阐明CDC37-Hsp90复合物通过磷酸化依赖性机制选择性识别并稳定致癌激酶(如AKT、ERK)，促进肿瘤细胞存活。
3. **"Targeting CDC37 in prostate cancer through antibody-mediated inhibition"**
*Authors: Shi Y, Thomas SD, Purcell JW, et al.*
摘要：研究开发了靶向CDC37的单克隆抗体，体外实验显示其能破坏CDC37-Hsp90与AR(雄激素受体)的相互作用，抑制前列腺癌细胞增殖及肿瘤生长。
---
*注：若需具体文献来源，建议通过PubMed或SciHub输入关键词“CDC37 antibody”或“CDC37 Hsp90”检索近年论文。*
**Background of CDC37 Antibody**
CDC37. a molecular chaperone, functions as a co-chaperone for heat shock protein 90 (HSP90), playing a critical role in stabilizing and activating client proteins, particularly protein kinases. It acts as a scaffold, facilitating the recruitment of kinase clients to the HSP90 complex, ensuring their proper folding, maturation, and functional activation. Dysregulation of CDC37 is implicated in cancer, where its overexpression supports the stability of oncogenic kinases (e.g., AKT, CDK4), promoting tumor progression and therapy resistance.
CDC37 antibodies are essential tools for studying its expression, localization, and interactions in cellular pathways. They are widely used in techniques like Western blotting, immunoprecipitation, immunofluorescence, and immunohistochemistry to investigate CDC37’s role in HSP90-mediated signaling, stress response, and disease mechanisms. Researchers also utilize these antibodies to explore therapeutic strategies targeting the CDC37-HSP90 axis, as disrupting this interaction may inhibit oncogenic kinase activity.
Recent studies highlight CDC37’s involvement in neurodegenerative diseases and immune regulation, broadening its clinical relevance. Antibodies against CDC37 thus serve as vital reagents for both basic research and drug development, aiding in biomarker discovery and the validation of novel inhibitors in preclinical models.
×
